Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors

Novartis0 个研究点目标入组 76 人开始时间: 2004年2月1日最近更新: 2023年10月12日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: Novartis
入组人数: 76
主要终点: Change from baseline systolic blood pressure at 8 weeks

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•- Patients who give consent
•Men and women 18 to 80 years of age
•Patients with hypertension (systolic >159 mm, diastolic >100 mm)
•Patients meeting laboratory criteria

排除标准

•- Pregnant women
•Women not using approved contraception methods
•Secondary hypertension
•Other protocol-defined exclusion criteria may apply.

结局指标

主要结局

Change from baseline systolic blood pressure at 8 weeks

次要结局

Blood pressure less than 140/90 mmHg at 8 weeks
Reduction from baseline in diastolic blood pressure greater than or equal to 10 mmHg
Reduction from baseline in systolic blood pressure greater than or equal to 20 mmHg

研究者

发起方

Novartis

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

4 期

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive PatientsHypertension

NCT00426478Novartis80

已完成

4 期

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With HypertensionHypertension

NCT00277472Novartis300

已完成

3 期

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionEssential Hypertension

NCT00902538Daiichi Sankyo2,204

进行中（未招募）

不适用

Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage - NDArterial Hypertension with organ damage

EUCTR2008-000804-10-ITIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II

已完成

4 期

Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.Hypertension

NCT00171561Novartis144